secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001104659-23-100256
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA CMO Schlienger resigns; Board member Dr. Peters named interim clinical lead
--------------------------------------------------------------------------------

- CMO Dr. Katia Schlienger resigns effective September 30, 2023 to pursue new opportunities.
- Board member Dr. Malte Peters, former MorphoSys R&D head, appointed Senior Clinical Advisor ad interim.
- CEO reaffirms focus on HB-200 randomized trial, HB-300 prostate program, and Roche/Gilead collaborations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465923100256/0001104659-23-100256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465923100256/tm2325987d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-100256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer